| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Article |
From Stanford University School of Medicine, Stanford, CA (AS); and the New York State Psychiatric Institute, New York, NY (SR).
Background: Despite the high prevalence of depression in elderly patients, few well-designed, placebo-controlled studies of antidepressants have been conducted in this population. This masked, placebo-controlled trial assessed the efficacy and safety of venlafaxine and fluoxetine in depressed patients older than 65 years.
Method: Three hundred patients were randomly assigned to treatment with venlafaxine immediate release ([IR]; N = 104), fluoxetine (N = 100), or placebo (N = 96) in an eight-week trial. Venlafaxine doses were titrated from 37.5 to 225 mg per day and fluoxetine doses were titrated from 20 to 60 mg per day, as necessary, over 29 days. Efficacy variables included the 21-item Hamilton Depression Rating Scale (HAM-D21) total score, HAM-D21 depressed mood item score, scores on the Montgomery Åsberg Depression Rating Scale (MADRS), Clinical Global Impression–Severity of Illness (CGI-S) and Improvement (CGI-I) scales, and rates of response (based on change from baseline HAM-D or MADRS score or CGI-I score) and remission (HAM-D17 
7). For the purposes of this report, efficacy analyses are focused on the HAM-D21 total score. Safety assessments included monitoring of adverse events (AEs), physical examinations, vital signs assessments, laboratory determinations, and electrocardiograms.
Results: In all three of the treatment groups, there was a significant reduction at week 8 compared with the baseline HAM-D21 total score. However, there were no significant differences among the three treatment groups on the change in HAM-D21, MADRS, or CGI scores from baseline to week 8. There was no statistically significant difference in the proportion of remitters at the last on-therapy visit. The incidence of individual AEs was higher in the venlafaxine group (27%) compared with patients taking fluoxetine (19%) or placebo (9%).
Conclusion: In this study, there was no significant difference in efficacy among placebo, venlafaxine, and fluoxetine for the treatment of depression.
Key Words: Depression • venlafaxine • fluoxetine
This article has been cited by other articles:
|
|
 |
|
  J. C. Nelson, K. Delucchi, and L. S. Schneider Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence Am J Geriatr Psychiatry, July 1, 2008; 16(7): 558 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bose, D. Li, and C. Gandhi Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older Am J Geriatr Psychiatry, January 1, 2008; 16(1): 14 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sneed, B. R. Rutherford, D. Rindskopf, D. T. Lane, H. A. Sackeim, and S. P. Roose Design Makes a Difference: A Meta-Analysis of Antidepressant Response Rates in Placebo-Controlled Versus Comparator Trials in Late-Life Depression Am J Geriatr Psychiatry, January 1, 2008; 16(1): 65 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Raskin, C. G. Wiltse, A. Siegal, J. Sheikh, J. Xu, J. J. Dinkel, B. T. Rotz, and R. C. Mohs Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial Am J Psychiatry, June 1, 2007; 164(6): 900 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lesperance, N. Frasure-Smith, D. Koszycki, M.-A. Laliberte, L. T. van Zyl, B. Baker, J. R. Swenson, K. Ghatavi, B. L. Abramson, P. Dorian, et al. Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial JAMA, January 24, 2007; 297(4): 367 - 379. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
